More than a decade after Human Longevity Inc. (HLI) raised hundreds of millions of dollars around a vision of data-driven preventive medicine, the company is doing something very different: taking clinical-grade whole-genome sequencing, once part of an $8,000 executive health program, directly to consumers for $599, while spinning out a separate AI company built on the biological data HLI has spent years collecting.
For CEO Dr. Wei-Wu He, the $599 genome is less a product than an entry point.
